SZShi-Bo Zhang

Shi-Bo Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Shi-Bo Zhang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Hai-Qing Li

    Department of Surgical Oncology, First Affiliated Hospital of China Medical University, 110001, Shenyang, Liaoning, China

    1 shared publication
  • Huimian Xu

    Department of Surgical Oncology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.

    1 shared publication
  • Jinyu Huang

    Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumours (China Medical University), Ministry of Education , Shenyang , China

    1 shared publication
  • Nan Jiang

    Institute of Health Sciences, China Medical University, Shenyang 110122, China

    1 shared publication
  • Qiong-Rui Zhao

    Department of Evidence Based Medicine, First Affiliated Hospital of China Medical University, 110001, Shenyang, Liaoning, China

    1 shared publication
  • Yu-Ying Lei

    Department of Oncology, Hebei General Hospital, Shijiazhuang, 050051, Hebei, China

    1 shared publication

Latest Publications

  • Open Access

    The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature

    by Yu-Ying Lei, Jin-Yu Huang, Qiong-Rui Zhao, Nan Jiang, Hui-Mian Xu, Zhen-Ning Wang, Hai-Qing Li, Shi-Bo Zhang, Zhe Sun

    Human epidermal growth factor receptor-2 (HER2) is regarded as an important and promising target in the treatment of HER2-positive breast cancers. However, the correlation of clinicopathological characteristics and prognostic significance of HER2 overexpression in gastric cancer patients remains unclear. Our aim was to clarify this issue. Embase, PubMed, and the Cochrane Library were searched for relevant articles published up to May 2016. Outcomes of interest contained sex, age, tumor size, tumor site, tumor node metastasis (TNM) stage, distant metastasis, lymph node metastasis, Lauren’s classification, differentiation grade, lymphovascular invasion, neural invasion, and multivariate analysis data for overall survival. A total of 41 studies of 17,494 gastric cancer patients were identified with HER2 test. HER2 positive rate was 19.07% (95% CI = 9.16, 28.98). There existed statistical significance between HER2 overexpression and patients’ prognosis (RR = 1.47, 95% CI = 1.09, 1.98). Male patients (OR = 1.48, 95% CI = 1.34, 1.65), proximal tumors (OR = 1.25, 95% CI = 1.07, 1.47), intestinal-type tumors (OR = 3.37, 95% CI = 2.54, 4.47), advanced stage cancers (OR = 1.35, 95% CI = 1.10, 1.66), lymph node metastasis (OR = 1.26, 95% CI = 1.14, 1.41), well-differentiated cancers (OR = 1.79, 95% CI = 1.15, 2.76), and distant metastasis (OR = 1.91, 95% CI = 1.08, 3.38) were correlated with higher HER2 expression rates. However, no statistical differences existed in age, tumor size, lymphovascular invasion, or neural invasion. Subgroup analysis revealed that HER2 expression rates reported in articles from Asian (19.52%) countries were quantitatively higher than those from European (16.91%) areas. Results were consistent with those reports that define HER2 status according to trastuzumab for gastric cancer (ToGA) criteria. This study showed that HER2 overexpression was associated with poor prognosis in gastric cancer patients. HER2 positive rates may be associated with sex, tumor site, TNM staging system, distant metastasis, lymph node metastasis, Lauren’s classification, and differentiation grade in gastric cancer patients. The HER2 expression rate in Asians may be higher than that in Europeans. This study offers a convenient way for doctors to select patients for relevant HER2 detection and following treatment.